Research ArticleTorilin Inhibits Inflammation by Limiting TAK1-MediatedMAP Kinase and NF-ğœ…B ActivationMehari Endale,1 Tae-Hwan Kim,2 Yi-Seong Kwak,3 Na-Mi Kim,3 Seung-Hyung Kim,4Jae Youl Cho,5 Bong-Sik Yun,6 andMan-Hee Rhee21Division of Neonatology and Pulmonary Biology, Cincinnati Childrenâ€™s Hospital Research Foundation, Cincinnati, OH, USA2College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea3Research and Development Headquarters, Korea Ginseng Corporation, Daejon 305-805, Republic of Korea4Institute of Traditional Medicine & Bioscience, Daejeon University, Daejeon 300-716, Republic of Korea5Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea6College of Environmental & Bioresource Sciences, Chonbuk National University, Iksan 570-752, Republic of KoreaCorrespondence should be addressed to Bong-Sik Yun; bsyun@jbnu.ac.kr and Man-Hee Rhee; rheemh@knu.ac.krReceived 9 October 2016; Accepted 27 December 2016; Published 20 February 2017Academic Editor: TaË†nia Silvia FroÂ¨deCopyright Â© 2017 Mehari Endale et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Torilin, a sesquiterpene isolated from the fruits of Torilis japonica, has shown antimicrobial, anticancer, and anti-inflammatoryproperties. However, data on the mechanism of torilin action against inflammation is limited.This study aimed at determining theanti-inflammatory property of torilin in LPS-induced inflammation using in vitro model of inflammation. We examined torilinâ€™seffect on expression levels of inflammatory mediators and cytokines in LPS-stimulated RAW 264.7 macrophages. The involvementof NF-kB and AP-1, MAP kinases, and adaptor proteins were assessed. Torilin strongly inhibited LPS-induced NO release, iNOS,PGE2, COX-2, NF-ğ›¼, IL-1ğ›½, IL-6, and GM-CSF gene and protein expressions. In addition, MAPKs were also suppressed by torilinpretreatment. Involvement of ERK1/2, P38MAPK, and JNK1/2 was further confirmed by PD98059, SB203580, and SP600125mediatedsuppression of iNOS and COX-2 proteins. Furthermore, torilin attenuated NF-kB and AP-1 translocation, DNA binding, andreporter gene transcription. Interestingly, torilin inhibited TAK1 kinase activation with the subsequent suppression of MAPK-mediated JNK, p38, ERK1/2, and AP-1 (ATF-2 and c-jun) activation and IKK-mediated I-ğœ…Bğ›¼ degradation, p65/p50 activation, andtranslocation. Together, the results revealed the suppression of NF-ğœ…B and AP-1 regulated inflammatory mediator and cytokineexpressions, suggesting the test compoundâ€™s potential as a candidate anti-inflammatory agent.1. IntroductionThe study of such inflammatory responses including inflam-matory mediators and cytokines activation is best charac-terized using suitable macrophage cell-lines including RAW264.7 cells as models. In macrophages, LPS activates Toll-like receptor-4 (TLR4) and the activated receptor recruitsthe adaptor proteins (e.g., MyD88 or TRAM) and initi-ates MyD88 dependent or independent signaling pathways.MyD88 recruits and associates with two IL-1R-associatedkinases (IRAK4 and IRAK1) leading to TNF receptor asso-ciated factor-6 (TRAF6) activation [1]. The activated TRAF6is then ubiquitinated and recruited to the TGFğ›½-activatedkinase 1 (TAK1)-TGFğ›½-activated kinase-1 binding protein1 and 2 (TAB1/2) complex via binding to TAB2 [2]. Thispromotes the activation of TAK1, which in turn activates thecanonicalNF-ğœ…B [2] and theMAPkinases signaling pathways[3]. TAK1-TAB1/2 complex is thus a common route for the Iğœ…Bkinase (IKK) and for MAPKs pathways (ERK1/2, JNK, andp38) [4]. These signaling pathways in turn activate a varietyof transcription factors including NF-kB (p50/p65) and AP-1 (c-Fos/c-Jun) that coordinate the induction of many genesencoding inflammatory mediators [5]. These mediators suchas iNOS, COX-2, and cytokines (TNF-ğ›¼, IL-1ğ›½, IL-6, andGM-CSF) are the common inflammatory mediators tran-scriptionally regulated by the above indicated transcriptionfactors [6]. Therefore, targeting these transcription factors,adaptor proteins, protein kinases, inflammationmediators, orHindawiMediators of Inï¬‚ammationVolume 2017, Article ID 7250968, 13 pageshttps://doi.org/10.1155/2017/72509682 Mediators of Inflammationcytokines themselves by natural products or their derivativescan be an effective strategy for immunosuppression [7].Natural products are reported to be better candidatesof therapeutics due to their chemical diversity, structuralcomplexity, affordability, lack of substantial toxicity, andinherent biologic activities [8]. Salminen et al. further indi-cated that a number of natural products have demonstratedNF-ğœ…B-inhibitory activities such as attenuation of IKK acti-vation, Iğœ…B degradation, NF-ğœ…B nuclear translocation, andDNA binding [9]. A large body of evidences also indicatedanti-inflammatory effects of natural products against MAPkinases. Modulation of NF-ğœ…B and MAP kinases signalingpathways is therefore a principal target to alleviate inflam-matory diseases including arthritis [10]. Recently, however,the demand for anti-inflammatory agents that can treatinflammation and arthritis but remain relatively free of sideeffects in long term treatment increases.A large number of plant-derived compounds includingnatural terpenoids as powerful inhibitors of NF-kB andMAPkinases are reported to be suppressive agents of inflammationand cancer [9, 11]. Evidently, a number of terpenoids arereported to affect some upstream targets as they inhibitthe NF-kB and MAPK pathways simultaneously and fur-ther potentiate the suppression of inflammatory responses[9, 12]. Sesquiterpenes are most widely published class ofnatural products cited as inhibitors of NF-ğœ…B. For instance,parthenolide, a sesquiterpenes, is reported to inhibit NF-ğœ…B via inhibition of Iğœ…Bğ›¼/Iğœ…Bğ›½ degradation [13] and IKKğ›½activation [14] and modification of NF-ğœ…B via alkylation[15â€“17]. However, information on the mechanism of anti-inflammatory property of torilin, another sesquiterpene, islimited.Torilin (11-acetoxy-8-angeloyl-4-guaien-3-one), a guai-ane-type sesquiterpene angelate, is isolated from the fruitsof the plant Torilis japonica [18]. Previous studies on torilinindicated that the compound exhibits antiprotozoal [19] andantimicrobial [20] effects. Besides, it is reported to reversemultidrug-resistance [21] and show antiangiogenic as well asanti-invasive properties [22, 23].Although few reports have been documented on the anti-inflammatory potential of torilin [24, 25], studies detailingthe mechanism of action behind its anti-inflammatory effectusing macrophage cells line (suitable models for studyinginflammatory responses) are limited. Since torilin has beenshown to possess anti-inflammatory activities in vitro andin vivo [24, 25], we previously have reported that torilinmodifies inflammatory cell and cytokine imbalances with theattenuation of the severity of arthritis in mouse model ofrheumatoid arthritis [26]. However, itsmolecularmechanismof action against inflammatory responses has not beenreported yet. The aim of this study was therefore to examinethe upstream events in the anti-inflammatory property oftorilin and to elucidate its underlying mechanisms of action.Here, we report that torilin markedly inhibited inflammatorymediators and cytokines via inhibition of TAK1-mediatedMAPK, AP-1, and NF-kB activation.2. Materials and MethodsPrimary antibodies for iNOS, COX-2, ğ›½-actin, PARP, pho-spho-PI3K p85, PI3K, Akt, phospho-Akt, NF-ğœ…B, phospho-NF-ğœ…B, Iğœ…B-ğ›¼, phospho-Iğœ…B-ğ›¼, IKKğ›½, phospho-IKKğ›¼/ğ›½,phospho-p38, p38MAPK, phospho-JNK, JNK, phospho-ERK1/2, ERK1/2, MKK4, MKK6, MyD88, IRAK1, TRAF6,phosphor-TAK1, TAK1, phospho-c-fos, phosphor-c-jun, pho-sphor-ATF2, IL-1ğ›½, TNFğ›¼, and horseradish peroxidase-conjugated secondary antibody were from Cell SignalingTechnology (Danvers, MA, USA). SB203580, SP600125, andPD98059 were from Sigma-Aldrich (St. Louis, MO). Con-sensus oligonucleotides for NF-ğœ…B and AP-1 were obtainedfrom Santa Cruz Biotechnology (Santa Cruz, CA). ğ›¾âˆ’32P-Labeled ATP was purchased from ICN (Costa Mesa, CA).A prostaglandin E2EIA kit was from Enzo life Sciences(Ann Arbor, MI, USA). Easy Blue RNA extraction kit wasfrom iNtRON, Korea. Millipore MILLIPLEXMouse Cyto-kine/Chemokine enzyme-linked immunosorbent assay kitwas from Millipore Corp. (St. Charles, MO). All materials,equipment, and biotinylated marker proteins for gel electro-phoresis were from Bio-Rad. All other chemicals were pur-chased from Sigma-Aldrich (St. Louis, MO) unless otherwisestated. Torilin (98%) was prepared as previously indicated in[26] and dissolved in dimethyl sulfoxide and freshly dilutedin culture media for all experiments.2.1. Cell Culture. RAW 264.7 murine macrophages, obtainedfrom theAmerican cell collection (ATCCTIB71), were growninDulbeccoâ€™smodifiedEagleâ€™smedium (DMEM) (Invitrogen,Carlsbad, CA), supplemented with 10% fetal bovine serum,2mM L-glutamine, 100UmLâˆ’1 penicillin, and 100 ğœ‡gmLâˆ’1streptomycin. They were incubated under endotoxin-freeconditions at 37âˆ˜C in a 5% CO2humidified air incubator.2.2. Cell Viability. The RAW 264.7 cells were plated at a den-sity of 5 Ã— 104 cells/well in a 96-well plate for 24 h. To deter-mine any potential cytotoxic effect of the test compound,cells were treated with torilin or vehicle before incubationfor 48 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide (MTT, 0.5mgmLâˆ’1) was added and cellswere incubated for 4 h. The media were then removed, andproduced formazan crystals in the wells were dissolved byaddition of 200mL dimethyl sulfoxide (DMSO). Absorbancewas measured at 540 nm using Synergy HT Multi-ModelMicroplate Reader (BioTek Instrument, Winooski, USA).Cell viability (% control) was defined relative to untreatedcontrol cells.2.3. Nitrite (NO) Production. RAW 264.7 macrophages wereplated in 96-well plates (2 Ã— 105 cells/well) and incubatedovernight. The cells were treated with torilin or vehicle30min before LPS stimulation for 24 h. NO productionwas determined via quantitation of nitrite levels in cellculture supernatants according to theGriess reactionwith theabsorbance measured at 540 nm.2.4. Enzyme-Linked Immunosorbent Assay. RAW 264.7 cellswere preincubated with torilin for 30min before LPS stimu-lation for 24 h, and cytokine contents in the culture mediumweremeasured by ELISA using anti-mouse TNF-ğ›¼, IL-1ğ›½, IL-6, and GM-CSF antibodies and biotinylated secondary anti-bodies following the manufacturerâ€™s instruction (MilliporeMILLIPLEX Mouse Cytokine/Chemokine kit (MilliporeMediators of Inflammation 3Corp., St. Charles, MO, USA)). In addition, PGE2contentsin the culture medium were measured using prostaglandinE2kit according to the manufacturerâ€™s instruction (Enzo lifeSciences, Ann Arbor, MI, USA).2.5. RNA Isolation and Reverse Transcription PCR. Totalcellular RNA from 3 Ã— 106 RAW 264.7 macrophages treatedwith torilin or vehicle was extracted as described previously[27] using Easy Blue kits (iNtRON Biotechnology, Korea)according to the manufacturerâ€™s instructions and storedat âˆ’70âˆ˜C until use. Briefly, 1 ğœ‡g RNA was annealed withpoly(dT)18for 10min at 70âˆ˜C and cooled for 5min on ice,reverse transcribed using reverse transcription (RT) premix(Bioneer) in 20 ğœ‡l of reaction mixture containing 5x buffer(10mM dNTP, 0.1mM dithiothreitol, and 2U of murineleukemia virus reverse transcriptase), and run for 90min at42.5âˆ˜C using a thermal cycler. The reactions were terminatedat 95âˆ˜C for 5min to inactivate the reverse transcriptase. Thereverse transcription polymerase chain reaction (RT-PCR)was performed using aliquots of cDNA obtained from RTreaction in a PCR premix (Bioneer) containing a 10x buffer[10mM Trisâ‹…HCl (pH 8.3), 50mM KCl, 0.1% Triton X-100,0.25mM dNTP, 25mM MgCl2, and 1 U of Taq polymerase].Amplification conditions were 5min before denaturation at95âˆ˜C followed by 30â€“35 cycles consisting of denaturationat 95âˆ˜C, annealing at 55â€“60âˆ˜C, and elongation at 72âˆ˜C for45 second each with final extension for 10min at 72âˆ˜C.The PCR products were electrophoresed in 1.3% agarose gelstained with ethidium bromide and visualized using EagleEyes image analysis software (Stratagene, La Jolla, CA). Theintensity of band densities for iNOS, COX-2, TNF-ğ›¼, IL-1ğ›½,IL-6, and GM-CSFmRNA expression levels were normalizedfor the corresponding GAPDH and ratios were compared.The sequence of oligonucleotides used was as follows: iNOS:(forward-5ó¸€ -GTG CTG CCT CTG GTC TTG CAA GC-3ó¸€ ,reverse-5ó¸€ -AGG GGC AGG CTG GGA ATT CG-3ó¸€ ); COX-2:(forward-5ó¸€ -TCT CAGCACCCACCCGCTCA-3ó¸€ , reverse-5ó¸€ -TCT CAG CAC CCA CCC GCT CA-3ó¸€ ); IL-1ğ›½: (forward-5ó¸€ -TGC TTC CAA ACC TTT GAC CTG GGC-3ó¸€ , reverse-5ó¸€ -CAG GGT GGG TGT GCC GTC TTT C-3ó¸€ ); TNF-ğ›¼:(forward-5ó¸€ -CCTGTAGCCCACGTCGTAGC-3ó¸€ , reverse-5ó¸€ -TTG ACC TCA GCG CTG AGT TG-3ó¸€ ); IL-6: (forward-5ó¸€ -GCT GGA GTC ACA GAA GGA GTG GC-3ó¸€ , reverse-5ó¸€ -GGC ATA ACG CAC TAG GTT TGC CG-3ó¸€ ); GM-CSF:(forward-5ó¸€ -ACT CTG CTC ACG AAG GAA CTC AGC-3ó¸€ , reverse-5ó¸€ -CAC AGC TCG GAA GAG CAT CGC A-3ó¸€ );GAPDH: (forward-5ó¸€ -CAC TCACGGCAAATTCAACGGC-3ó¸€ , reverse-5ó¸€ -CCT TGG CAG CAC CAG TGG ATG CAGG-3ó¸€ ).2.6. Immunoblotting. RAW 264.7 macrophages were washedwith PBS and lysed in standard lysis buffer [20mM Tris-HCl(pH 7.5), 1% Triton X-100, 137mMNaCl, 10% glycerol, 2mMEDTA, 1mM sodium orthovanadate, 25mM ğ›½-glycero-phosphate, 2mM sodium pyrophosphate, 1mM phenyl-methylsulfonyl fluoride and 1mgmLâˆ’1 leupeptin, 2mgmLâˆ’1aprotinin, and 1mgmLâˆ’1 pepstatin A]. Lysates were cen-trifuged at 10,000Ã—g for 10min and supernatant was storedat âˆ’70âˆ˜C until use. Protein was then measured usingBicinchoninic Acid (BCA, Pierce, USA) protein assay kitwith bovine serum albumin used as a standard. Equalamounts of protein (30â€“40ğœ‡g/lane) were loaded with samplebuffer (250mM Tris-HCl, pH 6.8, 0.5M DTT, 10% SDS,50% glycerol, 5%ğ›½-mercaptoethanol, and 0.5% bromophenolblue) and electrophoresed on 8â€“12% SDS-polyacrylamide gelunder standard conditions and electroblotted to polyvinyli-dene difluoride membranes (PVDF) (Millipore Co., MA,USA) in 20% methanol transfer buffer. The membraneswere washed three times with Tris-buffered saline containing0.01% Tween-20 (TBS-T) and blocked with 5% nonfat milk,washed, and incubated with primary antibodies diluted(1 : 1000) overnight at 4âˆ˜C. The membranes were then incu-batedwith secondary antibodies conjugatedwith horseradishperoxidase for 1 h at room temperature. Scanning densito-metry of the immunoblots was performed with an ImageScan and Analysis System (Alpha-Innotech, San Leandro,CA, USA). The area of each lane was integrated using thesoftware Alpha Ease version 5.5 (Alpha-Innotech) followedby background subtraction.2.7. Immunoprecipitation and In Vitro TAK1 Kinase Assays.Cell lysates containing equal amounts of protein (500 ğœ‡g)from RAW 264.7 (107 cells/ml) treated with torilin or vehicle30min before LPS stimulation for 15min were preclearedwith 10 ğœ‡L proteinA-coupled Sepharosemagnetic beads (10%v/v; ELPIS Biotech, Korea) for 1 h at 4âˆ˜C. Precleared sampleswere incubated with 3 ğœ‡L anti-TAK1 antibody overnight at4âˆ˜C. Immune complexes were mixed with 10 ğœ‡L protein A-coupled Sepharose magnetic beads (10% v/v) and incubatedfor 4 h at 4âˆ˜C. The immune-precipitates were then washed5 times with immunoprecipitation (IP) buffer (20mM Tris-HCl, pH 7.4; 2mM EDTA, 2mM EGTA, 50mM ğ›½-glycero-phosphate, 5mM NaF, 1mM sodium orthovanadate, 1%Triton X-100, 10% glycerol, 10ğœ‡g/ml aprotinin, 10 ğœ‡g/mlpepstatin, 1mMPMSF, 1mMbenzimide, and 2mMhydrogenperoxide). After washing, the beads were boiled in Laemmlisample buffer (2% sodium dodecyl sulfate [SDS], 1%ğ›½-mercaptoethanol, 0.008% bromophenol blue, 80mMTris pH6.8, and 1mM EDTA) and the proteins were resolved bySDS-PAGE and transferred to PVDF membranes, blocked,and probed with anti-p-TAK1, TAK1, p-IKKğ›¼/ğ›½, IKK, p-MKK4, MKK4, anti-TLR4, and ğ›½-actin antibodies. Then,immunoblots were visualized as indicated above.For evaluating TAK1 kinase activities following immuno-precipitation, the beads were washed in IP buffer and then inkinase reaction buffer [100mMTris-HCl, pH 7.2; 125mMMg(C2H3O2)2; 25mM MnCl2; 2mM EGTA; 0.25mM sodiumorthovanadate; and 2mM DTT] and then resuspended inkinase buffer containing 1 ğœ‡mATP and 12.5 ğœ‡Ci of ğ›¾âˆ’32. After5min of incubation at 30âˆ˜C, the reaction was terminated bylysis buffer.2.8. Preparation of Nuclear Extracts. Prior to nuclear extrac-tion, cells (5 Ã— 106/well) were washed twice with ice-coldPBS centrifuged and the pellet was suspended by adding400 ğœ‡l of buffer A [10mMHEPES (pH 7.9), 10mMKCl, 2mMMgCl2, 0.1mM EDTA, 1mM dithiothreitol and 0.5mM4 Mediators of Inflammationphenylmethylsulfonyl fluoride (PMSF), 2 ğœ‡gmLâˆ’1 of leu-peptin, aprotinin, and pepstatin]. After centrifugation at10,000Ã—g for 5min, pellet was resuspended with buffer Aand 5% Nonidet-P40 and centrifuged at 13,000Ã—g for 2minand the supernatant was used as cytosolic extract. The pelletscontaining crude nuclei were resuspended in 400 ğœ‡l bufferA centrifuged at 10,000Ã—g for 5min twice. The pellets wereagain resuspended with buffer B containing 10mM HEPES[(pH 7.9), 300mM NaCl, 0.1mM EDTA, 1mM DTT and1mM PMSF, 5 ğœ‡gmLâˆ’1 leupeptin, aprotinin, and pepstatineach and 10% glycerol] and incubatedwith rocking for 20minon ice. The samples were centrifuged at 15,800Ã—g for 10minto obtain the supernatant containing nuclear extracts. Proteinconcentration of the supernatant was determined.2.9. Electrophoretic Mobility Shift Assay. RAW 264.7 macro-phages (3 Ã— 106 cells) were treated with torilin or vehicleand stimulated with LPS for 45min, washed, scraped into0.5ml cold PBS, and pelleted by centrifugation. Cytosolicand nuclear protein fractions were extracted using activemotif nuclear extraction kit (Carlsbad, CA, USA). Bindingreactions were performed at 37âˆ˜C for 15min in 20ğœ‡l ofreaction buffer containing [10mM Tris-HCl, pH 7.5, 50mMNaCl, 1mM EDTA, 10% glycerol, 1 ğœ‡g poly(dI-dC), 1mMdithiothreitol, and 30,000 cpm 32P-labeled oligonucleotideprobes] for NF-ğœ…B and AP-1. DNA-protein complexes wereseparated from unbound DNA probe on native 6% polyacry-lamide gels at 75V in 0.5x TBE buffer and then transferred tonylon membrane.2.10. Transient Transfection Luciferase Assay. Transient trans-fections of RAW 264.7 cells with MyD88, NF-ğœ…B, and AP-1 promoter firefly luciferase construct were performed intriplicate in 24-well plates using Lipofectamine 2000 (Invit-rogen, CA, USA). The reporter activity was measured usinga luciferase assay system according to the manufacturerâ€™sinstructions. Briefly, 6 hr after treatment, cells were washedtwice with ice-cold PBS (pH 7.4) and lysed by adding 200ğœ‡lof 1x reporter lysis buffer (Promega). After centrifugation at12,000Ã—g for 10min at 4âˆ˜C, the supernatant was analyzed forluciferase activity and normalized to ğ›½-galactosidase activity.2.11. Statistical Analysis. Data were analyzed by one-wayanalysis of variancewithDunnettâ€™s post hoc test. Experimentsrepresent at least 4 independent replications in triplicate.Values are means Â± SE and treatment groups were comparedby t-test. ğ‘ƒ < 0.05 was considered statistically significant.3. Result3.1. Torilin Inhibits LPS-Induced Inflammatory Mediator andCytokine Expressions. Because torilin has been described assesquiterpene with anti-inflammatory activity in BV2 cells[25], we examined the anti-inflammatory mechanisms ofthe compound using a suitable macrophage RAW 264.7cell-line model. Toxicity screening showed that torilin didnot exhibit cytotoxicity in RAW 264.7 (SupplementaryFigure 1 in Supplementary Material available online athttps://doi.org/10.1155/2017/7250968). Torilin pretreatmentdose-dependently inhibitedNOgeneration and iNOSproteinand gene expressions (Figures 1(a), 1(c), and 1(d)), respec-tively. In addition, prostaglandin (PG)E2 and COX-2 proteinand mRNA expressions were markedly suppressed by torilin(Figures 1(b), 1(e), and 1(f)). Torilin further arrested LPS-induced proinflammatory cytokines including TNF-ğ›¼, IL-1ğ›½,IL-6, and GM-CSF protein secretion (Figures 2(a)â€“2(d)) andprotein and mRNA expressions (Supplementary Figure 2A-F), respectively.These data suggested that torilinmay elicit itsoverall anti-inflammatory effects at the level and/or upstreamof inflammatory gene transcriptions.3.2. Effect of Torilin on LPS-Induced MAP Kinases and PI3k-Akt Activation. We examined the possible involvement ofMAPK and PI3K/Akt signaling pathways in torilin mediatedinhibition of inflammatory mediators. As shown in Figures3(a) and 3(b), torilin significantly suppressed LPS-inducedERK1/2, p38, and JNK1/2 activation in a dose dependentmanner while it had no effect on PI3k/Akt phosphorylation(Supplementary Figure 3). This observation was furtherconfirmed by the suppressive effects of the respective MAPkinases inhibitors PD98059 (ERK-inhibitor), SB203580 (p38-inhibitor), and SP600125 (JNK-inhibitor) on iNOS andCOX-2 expressions (Figure 3(c)). The result suggests that theanti-inflammatory effect of torilin is correlated with MAPKinactivation.3.3. Torilin Inhibited I-ğœ…B Phosphorylation and NF-ğœ…B Acti-vation. To further investigate the molecular mechanisminvolved in the torilin mediated inhibitions of inflammatorymediator and cytokine transcriptions observed in this study,we examinedwhetherNF-ğœ…B and/orAP-1 signaling pathwaysare involved. As shown in Figure 4(a), LPS stimulationmarkedly triggered I-kBğ›¼ phosphorylation with a concurrentdecrease in total I-kB expression especially at 15 and 30minLPS stimulation. Torilin pretreatment strongly and time-dependently inhibited I-kBğ›¼ phosphorylation and restoredtotal I-kB depletion (Figure 4(a)). Since phosphorylation ofI-kBğ›¼ precedes degradation of I-kBğ›¼ and subsequent releaseof NF-ğœ…B, we also examined the effect of torilin treatment onNF-ğœ…B activation and translocation.3.4. Torilin Inhibits NF-ğœ…B and AP-1 Nuclear Translocation,DNA Binding, and Reporter Activities. Since, without enter-ing the nucleus, NF-ğœ…B cannot regulate transcription, weinvestigated effect of torilin treatment on LPS-induced NF-ğœ…B translocation, DNA binding, and reporter gene activity.The p65 and p50 nuclear translocation was analyzed fromcytosolic and nuclear protein fractions at a given time inter-val. Torilin significantly reduced LPS-induced cytosolic p65and p50 expressions (Figure 4(b)). The nuclear translocationof NF-ğœ…B was markedly observed from an increased LPS-induced p65 and p50 nuclear protein expression levels thatwere significantly inhibited by torilin treatment (Figure 4(c)).In addition to NF-ğœ…B activation (Supplementary Figure 4),immunoblotting revealed that LPS-induced AP-1 subunit(ATF-2 and c-jun but not c-fos) activation was also inhibitedby torilin treatment (Supplementary Figure 5).Mediators of Inflammation 5Nitrite (ğœ‡M)35302520151050âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—LPS (100ngmLâˆ’1)Torilin (ğœ‡M) 6.25 502512.5âˆ’âˆ’(a)LPS (100ngmLâˆ’1)Torilin (ğœ‡M) 502512.5âˆ’âˆ’âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—PGE2production (pgmLâˆ’1)25002000150010005000(b)iNOSğ›½-ActiniNOS/ğ›½-actin proteinâˆ—âˆ—âˆ—âˆ—âˆ—âˆ—6.25 2512.5LPS (100ngmLâˆ’1)Torilin (ğœ‡M) âˆ’ âˆ’1.00.80.60.40.20.0(c)GAPDHiNOS/GAPDH mRNA iNOSâˆ—âˆ—âˆ—âˆ—âˆ—âˆ—3.13 2512.56.25LPS (100ngmLâˆ’1)Torilin (ğœ‡M) âˆ’ âˆ’10.80.60.40.20(d)ğ›½-ActinCOX-2COX-2/ğ›½-actin protein1.41.21.00.80.60.40.20.06.25 2512.5LPS (100ngmLâˆ’1)Torilin (ğœ‡M) âˆ’ âˆ’âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—(e)GAPDHCOX-2COX-2/GAPDH mRNA 3.13 2512.56.25LPS (100ngmLâˆ’1)Torilin (ğœ‡M) âˆ’ âˆ’0.60.40.20âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—(f)Figure 1: Torilin inhibits LPS-induced NO release, PGE2 secretion, and protein as well as mRNA expression of iNOS and COX-2 enzymes.RAW246.7macrophages were pretreatedwith torilin or vehicle for 30min and stimulatedwith LPS for 18 or 24 h. (a) Cell culture supernatantswere analyzed for nitrite release, as a measure of NO production. (b) PGE2secretion in culture media was analyzed in torilin treated RAWcells as described in Materials andMethods. After 24 h of stimulation for protein expression (c) and 18 h of stimulation for mRNA expression(d) were depicted, respectively. Again, COX-2 protein (e) andmRNA (f) were determined by western blot and RT-PCR, respectively. GAPDHand ğ›½-actin were used as controls for mRNA and protein loading, respectively. Images are representative of 3 or 4 independent experiments.Values in bar graphs aremeansÂ± SE of at least 4 independent experiments performed in triplicate. Significancewas determined using Studentâ€™st-test versus the control group. âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01, âˆ—âˆ—âˆ—ğ‘ƒ < 0.001 versus LPS.To examine whether torilin attenuates LPS-induced NF-kB and/or AP-1 DNA binding, we conducted EMSA analyses.As shown in Figures 5(a) and 5(b), torilin at the doses of25 and 50 ğœ‡M demonstrated a selective reduction in NF-ğœ…BandAP-1DNAbinding. To further investigate whether torilinattenuates promoter activities of the indicated transcriptionfactors, we tested luciferase reporter gene transcription.Incubation of transfected RAW 264.7 cells with LPS for 6 h6 Mediators of InflammationLPS (100ngmLâˆ’1)Torilin (ğœ‡M) 6.25 2512.5âˆ’âˆ’TNF-ğ›¼secretion (pgmLâˆ’1) 6000500040003000200010000âˆ—âˆ—(a)LPS (100ngmLâˆ’1)Torilin (ğœ‡M) 6.25 2512.5âˆ’âˆ’IL-1ğ›½secretion (pgmLâˆ’1) 14000120001000080006000400020000âˆ—âˆ—(b)LPS (100ngmLâˆ’1)Torilin (ğœ‡M) 6.25 2512.5âˆ’âˆ’IL-6 secretion (pgmLâˆ’1)1400012000100008000600040002000016000âˆ—âˆ—âˆ—(c)LPS (100ngmLâˆ’1)Torilin (ğœ‡M) 6.25 2512.5âˆ’âˆ’GM-CSF (pgmLâˆ’1)6000500040003000200010000âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—(d)Figure 2: Torilin pretreatment reduces LPS-induced proinflammatory cytokine secretions into the culture media. RAW 264.7 cells werepretreatedwith torilin or vehicle for 30min and stimulatedwith LPS for 24 h. TNF-ğ›¼ (a), IL-1ğ›½ (b), IL-6 (c), andGM-CSF (d) were determinedusing ELISA. Each bar graph represents mean Â± (SE) for four independent experiments. Significance was determined using Studentâ€™s t-test.âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01, âˆ—âˆ—âˆ—ğ‘ƒ < 0.001.increased luciferase activity. However, the increased NF-ğœ…Band AP-1 reporter gene activities were suppressed in torilin-sensitive manner (Figures 5(c) and 5(d)), suggesting that thecompoundâ€™s inhibitory effect is associated with reduced NF-kB- and AP-1-DNA binding and promoter activities.3.5. Torilin Suppressed Iğœ…B Kinase-ğ›¼/ğ›½ (IKKğ›¼/ğ›½) Activation.Since activation of NF-ğœ…B is induced by a cascade of signalingevents leading to the activation of IKK complex, which inturn phosphorylates Iğœ…B [28, 29], we determined torilininfluence on LPS-induced IKKğ›¼/ğ›½ activation. In parallel withits inhibition on LPS-induced phosphorylation and Iğœ…Bğ›¼degradation (Figure 4(a)), torilin suppressed IKKğ›¼/ğ›½ activa-tion at the indicated time course (Figure 6(a)), suggestingthat LPS-induced kinase activity may be impaired by thetest compound that ultimately leads to an inhibition inIKK-mediated Iğœ…Bğ›¼ phosphorylation and NF-ğœ…B regulatedinflammatory response. However, it is worth noticing thatNF-ğœ…B is not the only pathway that could be modified bytorilin because phosphorylation of IKKğ›¼/ğ›½ is also regulatedby other upstream factors such as MAPKs, including ERK,JNK, and p38. We, indeed, affirmed that torilin markedlysuppressed the upregulation of these kinases after LPSstimulation (Figures 3(a) and 3(b)), suggesting that torilinaffects some upstream targets as they inhibit the NF-kB andMAPK pathways simultaneously and further potentiate thesuppression of inflammatory responses.3.6. Torilin Inhibits LPS-Induced TAK1 Activation and Mul-tiple Components of Downstream Signaling Pathway. Sinceour data showed that torilin affects both IKKğ›¼/ğ›½ and MAPKdownstream pathways, we thought that its inhibitory effectmight involve upstream common pathway that lies betweenTLR4 andMAP3K complexes. Interestingly, immunoblottinganalysis revealed that while torilin did not affect LPS-stimulated activation of MyD88, IRAK1, and TRAF6 (datanot shown), it markedly inhibited TAK1, MKK4, and IKKğ›¼/ğ›½activation (Figures 6(a) and 6(b)). Since Shim et al. foundthat TNFR1, IL-1R, TLR3, and TLR4-mediated NF-ğœ…B andAP-1 activation are severely impaired in TAK1 deficient cells,but not in TAK1-binding protein 1 and 2 (TAB1/2) deficientcells [30], and since torilin did not affect MyD88, IRAK1, andTRAF6 downstream of TLR4 but suppressed the signalingeffects thereafter we further examined the test compoundâ€™seffect at the level of MAP3K complexes. TAK1 was immuno-precipitated from LPS-stimulated untreated cells and fromcells treated with torilin, as indicated in Figure 6(d). Theimmunoprecipitates were separated on SDS-PAGE, and themembrane was blotted with an antibody that recognizes p-TAK1, TAK1, p-MKK4, MKK4, p-IKKğ›¼/ğ›½, and IKK ğ›¼/ğ›½.TAK1 precipitation increased LPS-induced p-TAK1 activationand brought down the basal TAK1 protein expression, theevent of which was reversed by torilin treatment (Fig-ure 6(d)). We were also able to detect torilin mediatedinhibition of MKK4 and IKKğ›¼/ğ›½ phosphorylation while theMediators of Inflammation 7P-ERK1/2P-P38P38P-JNKJNKğ›½-ActinERK1/2MAP Kinase expression âˆ’ âˆ’ 6.25 2512.5âˆ’ + + + +ğ›½-ActiniNOSCOX-2âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)âˆ’ + + + + +Torilin (25 ğœ‡M) âˆ’ âˆ’ + âˆ’ âˆ’ âˆ’SP600125 (ğœ‡M) âˆ’ âˆ’ âˆ’ âˆ’ âˆ’ +PD98059 (ğœ‡M) âˆ’ âˆ’ âˆ’ + âˆ’ âˆ’SB203580 (ğœ‡M) âˆ’ âˆ’ âˆ’ âˆ’ + âˆ’LPS (0.1ğœ‡gmLâˆ’1)1.41.21.00.80.60.40.20.0p-ERK1/2p-p38p-JNK(a)(b)(c)Figure 3: Effect of torilin on mitogen activated protein kinase (MAPK) activation. LPS-stimulated RAW 264.7 macrophages were treatedwith vehicle or torilin (6.25â€“25ğœ‡M) and stimulated with LPS for the indicated periods of time. Total protein was subjected to western blotanalyses using total and phospho-anti-RK1/2, p38MAPK, and JNK1/2 antibodies. Torilin suppressed phosphorylation of the three MAPKs (aand b). Cells were further pretreated with vehicle or PD98059 (30ğœ‡M), ERK1/2 inhibitor, SB203580 (10ğœ‡M), p38MAPK inhibitor, or SP600125(10ğœ‡M), JNK1/2 inhibitor, with torilin and stimulated with 100 ngmLâˆ’1 LPS as indicated in (c). Significance was determined using Studentâ€™st-test versus the control group. Images are representative of 3 or 4 independent experiments. Values in bar graphs are means Â± SE of at least4 independent experiments performed in triplicate. âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01, âˆ—âˆ—âˆ—ğ‘ƒ < 0.001 versus LPS.basal activities of these kinases were not affected in torilintreated and TAK1 precipitated lysates. Interestingly, torilinfurther inhabited LPS-stimulated TAK1 kinase activation(Figure 6(c)), suggesting torilinâ€™s upstream inhibitory effectat the level of MAP3k complex early in the signaling eventthrough the inhibition of TAK1 activation with a markedlimitation of LPS-induced NF-ğœ…B and MAPKs stimulation.4. DiscussionThe promotion of inflammatory conditions and the initi-ation of the innate immune response require the releaseof many special effector proteins, the synthesis of which istranscriptionally regulated by inducible transcription factorsthat bind to the promoter regions of their respective genes.Such effectors (mediators of inflammation) include iNOS,COX-2, and cytokines (TNF-ğ›¼, IL-1, IL-6, andGM-CSF).NF-ğœ…B and AP1 are among the principal inducible transcriptionfactors that play pivotal roles in innate immune response [31]and chronic inflammatory conditions such as rheumatoidarthritis [32]. Recently, the demand for natural productslimiting induction of inflammatory mediators with minimalside effects is growing.For decades, numerous studies have been reported tosupport the promise that natural products and phytochem-icals could be protective against the risk of various types ofinflammation and a large body of evidence indicated the anti-inflammatory effects of these compounds in terms of theiraction against kinases, adaptor proteins, the transcriptionfactors, such as NF-ğœ…B and AP-1, and the genes regulated bysuch transcription factors [8, 9, 11, 33].Sesquiterpenes, plant-derived compounds, are reportedto modulate NF-ğœ…B and AP-1 transduction pathways andinhibit inflammatory mediators and inflammatory processesthat help alleviate the symptoms of inflammatory diseasesincluding arthritis [9, 11]. Since, torilin, a sesquiterpene,8 Mediators of Inflammationâˆ—âˆ—âˆ—âˆ—âˆ—âˆ—I-ğœ…BP-I-ğœ…Bğ›¼I-ğœ…B phosphorylation###ğ›½-Actinâˆ’ +âˆ’ +âˆ’+++âˆ’+++âˆ’+Time (min)6030150Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)1.21.00.80.60.40.20.00 15 30 60âˆ’ âˆ’ + âˆ’ + âˆ’ + Time (min) LPSTorilin (25ğœ‡M)I-ğœ…BPhospho-I-ğœ…Bğ›¼(a)âˆ—âˆ—âˆ—âˆ—âˆ—Cytoplasmic-p65Cytoplasmic-p50ğ›½-Actin0 15 30 60âˆ’ âˆ’ + âˆ’ + âˆ’ + Cytoplasmic NF-ğœ…B expressionâˆ’ âˆ’ + âˆ’ + âˆ’ +âˆ’ + + +Time (min)6030150Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)1.41.21.00.80.60.40.20.0Time (min) LPSTorilin (25ğœ‡M)Cytosolic p65Cytosolic p50(b)Nuclear-p65Nuclear-p50PARPâˆ’ âˆ’ + âˆ’ + âˆ’ +âˆ’ + + +Time (min)6030150Nuclear p65 and p50 NF-ğœ…B expressionâˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—LPS (0.1ğœ‡gmLâˆ’1)1.61.41.21.00.80.60.40.20.00 15 30 60âˆ’ âˆ’ + âˆ’ + âˆ’ + Time (min) LPSTorilin (25ğœ‡M)Torilin (25ğœ‡M)Nuclear p65Nuclear p50(c)Figure 4: Torilin restores I-ğœ…Bğ›¼ phosphorylation and degradation; thereby it inhibits p65-NF-ğœ…B nuclear translocation. (a) RAW 264.7 cellswere pretreated with the indicated concentrations of torilin for 30min and incubated with LPS (100 ng/ml) for (15â€“60min) time courseand then assayed for the phosphorylation and degradation of I-ğœ…Bğ›¼ and nuclear translocation of p65 by western immunoblot analysis asdescribed under Materials and Methods. (b and c) RAW macrophages were treated with LPS (100 ngmLâˆ’1) and 25ğœ‡M torilin, respectively,for the indicated time course before cytoplasmic and nuclear protein fractions were subjected to western blot analyses for p65 (upper panel)and p50 (middle panel) of cytoplasmic (b) and nuclear (c) proteins, respectively.ğ›½-Actin and ploy(ADP-ribose) polymerase (PARP)were usedas a control for the cytoplasmic and nuclear protein loading, respectively. Images are representative of 3 or 4 independent experiments. Valuesin bar graphs aremeans Â± SE of at least 4 independent experiments performed in triplicate. Significance was determined using Studentâ€™s t-test.âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01, âˆ—âˆ—âˆ—ğ‘ƒ < 0.001. #The significance of IkB degradation upon LPS activation associated with p-IkB phosphorylation incomparison with torilin treated group as analysed from western blot band size.Mediators of Inflammation 9âˆ’ âˆ’ 25NF-ğœ…BnsTorilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)50(a)AP-1nsâˆ’ âˆ’ 25Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)50(b)NF-ğœ…B reporter activity (%)âˆ’ âˆ’ 12.5 25âˆ’ + + +Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)âˆ—âˆ—âˆ—300025002000150010005000(c)AP-1 reporter activity (%)âˆ’ âˆ’ 12.5 25âˆ’ + + +Torilin (ğœ‡M)LPS (0.1ğœ‡gmLâˆ’1)âˆ—âˆ—9008007006005004003002001000(d)Figure 5: Torilin arrests AP-1 and NF-ğœ…BDNA binding and reporter gene expression in LPS-stimulated RAW 264.7 cells. RAWmacrophageswere treated with vehicle or torilin (as indicated) and stimulated with LPS for 45 min before nuclear protein was isolated. DNA bindingwas analyzed using specific ğ›¾32P-labeled oligonucleotide probes for NF-ğœ…B (a) or AP-1 (b). Specificity was demonstrated by coincubationwith a 25-fold excess of unlabeled specific probe of NF-ğœ…B and AP-1 for competition. Cells were transiently transfected with NF-ğœ…B (c) orAP-1 (d), plasmids treated with the indicated concentrations of torilin and LPS (100 ngmLâˆ’1) for 6 h and assayed for CAT expression usinga CAT enzyme-linked immunosorbent assay kit. Each column shows the mean Â± SEM of quadruplicate determinations. Luciferase activitywas normalized to ğ›½-galactosidase activity. Images are representative of 3 independent experiments. âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01, as compared withvehicle.has been shown to possess anti-inflammatory activities invitro and in vivo [24, 25], we, using mouse model ofrheumatic arthritis, have previously reported that torilinmodifies inflammatory cell and cytokine imbalances withthe attenuation of the severity of arthritis [26]. We, herefurther, report the in vitro inhibitory effect of torilin inLPS-inducible inflammatory mediators and proinflamma-tory cytokines and propose the underlying mechanism ofaction in LPS-stimulated RAW 264.7 cells. The mediatorsof inflammation protein secretion and mRNA expressionsrevealed that torilin effectively blocked the LPS-stimulatedNO generation, PGE2 synthesis, and iNOS and COX-2protein and mRNA expressions, respectively. In addition,LPS-activated TNF-ğ›¼, IL-1ğ›½, IL-6, and GM-CSF proteinsecretions and gene expressions are markedly inhibited bytorilin treatment, suggesting that the test compoundâ€™s wide-spectrum effect on inflammatory mediators might arise fromits influence on the upstream common signaling pathway.This study examined the involvement of MAPKs as amolecular target for torilin mediated inhibition of LPS-indu-ced inflammatory mediators and proinflammatory cyto-kine inductions. All the three MAPKs, that is, ERK1/2,p38MAPK and JNK1/2, were markedly suppressed by torilinpretreatment.Using the selectiveMAPK inhibitors, PD98059,SB203580, and SP600125, we further confirmed that block-ade of the indicated MAPK activities by their respectiveinhibitors suppressed iNOS and COX-2 expressions. More-over, torilin arrested AP1 transactivation and its subunits(ATF2, c-jun, and c-fos) phosphorylation. This observationsuggests that the inhibitory effect of torilin on iNOS andCOX-2 induction was at least partly regulated via MAPKsmediated AP1 transactivation. In agreement with our data,several lines of evidence documented the essential roles ofMAPKs in regulating LPS-induced inflammatory responses.MAPK cascades mediate LPS-stimulated induction of COX-2 and IL-1ğ›½ in RAW264 macrophages [34]. Likewise, ERKand p38 subgroups of MAPKs regulate iNOS and TNF-ğ›¼ gene expressions in endotoxin-stimulated glial cells [35],and p38MAPK also plays role in IL-1ğ›½ transcription [36].Hwang et al. have reported blockade of ERK1/2 and p38MAPKactivities by PD98059 and SB203580, respectively, resulting inpartial suppression of LPS-induced COX-2 expression [37],and monocytes treated with LPS in the presence of MEKinhibitor U0126 failed to release cytokines and PGE2 [38],supporting the notion that the MAPK pathway is criticalfor inflammatory response and torilin with the inhibitory10 Mediators of InflammationP-IKKğ›¼/ğ›½IKKIKKğ›¼/ğ›½ğ›½-ActinLPS (ğœ‡g/ml) 301550âˆ’ âˆ’ + âˆ’ + âˆ’ +âˆ’ âˆ’ + âˆ’ + âˆ’ +âˆ’ + + + + + +Time (min)6030150IKK activationâˆ—âˆ—âˆ—âˆ—âˆ—âˆ—LPS (0.1ğœ‡gmLâˆ’1)Torilin (25ğœ‡M)Torilin (25ğœ‡M)1.61.41.21.00.80.60.40.20.0Phospho-IKKğ›½(a)ğ›½-ActinMKK4P-MKK4TAK1P-TAK1min60301550âˆ’ âˆ’ + âˆ’ + âˆ’ + âˆ’ +g/ml)LPS (1 ğœ‡Torilin (25ğœ‡M)(b)0 6.25 12.5TAK1 kinase activity (%)+ + +Torilin (ğœ‡M)g/ml)LPS (1 ğœ‡âˆ—100806040200(c)IB: P-TAK1IB: TAK1IB: P-MKK4IB: P-IKKğ›¼/ğ›½IB: MKK4IB: IKKIB: ğ›½-actinâˆ’ + +âˆ’ âˆ’ +IP: TAK115 ming/ml)LPS (1 ğœ‡Torilin (25ğœ‡M)(d)Figure 6: Torilin suppresses LPS-induced IKK and MAP3K complex activation and inhibits the TAK1 interaction with the components ofMAPK and NF-ğœ…B signaling pathways. RAW macrophage cells were incubated with torilin or vehicle for 30 min and then stimulated withLPS as indicated in the figures. (a) Lysates from torilin or vehicle treated-cells were immunoblotted to detect the activation status of IKK.(b) Immunoblots depicting the time dependent effects of torilin in TAK1, MKK4, and IKK phosphorylation. (c) The kinase activity of theTAK1 was determined after immunoprecipitates were resuspended in kinase buffer and assayed for kinase activity as described in Materialsand Methods. (d) Cell lysates were immunoprecipitated by incubating overnight with anti-TAK1 antibody and then incubated with proteinA-Sepharose (PAS) for 4 h at 4âˆ˜C. Precipitated proteins were separated by SDS-PAGE and immunoblotted to detect P-TAK1, TAK1, p-MKK4,MKK4, p-IKKğ›¼/ğ›½, IKK, and ğ›½-actin. Equivalent protein loading was verified by reprobing for the respective total antibodies and ğ›½-actin.Images are representative of 4 or more independent experiments. Values in bar graphs are means Â± SE of at least 4 separate experimentsperformed in triplicate. âˆ—ğ‘ƒ < 0.05, âˆ—âˆ—ğ‘ƒ < 0.01 versus control.Mediators of Inflammation 11potential of this pathway could be a better candidate againstinflammation.In agreement with our study, an isolated report indicatedanti-inflammatory effect of torilin in BV2 cells [25]. Theauthors reported that torilin inhibits iNOS, COX-2, PGE2,and IL-1ğ›½ activation and they suggested that torilin mediatedinhibition of ERK or p38 but not JNK activation is one ofthe possible mechanisms underlying its inhibitory action oniNOS expression and NO production [25]. The discrepancyon JNK activation between the reported study and the presentinvestigation may be due to the difference in cells used in therespective studies. In line with this, negative regulation of p38and IKK activation by TGF-ğ›½-activated kinase 1 (TAK1) wasobserved in a cell type-specific manner [39]. However, torilinaction against a wide range of LPS-induced inflammatorymediators, MAPKs, and transcription factors suggests thatupstream pathway early signaling event may be affected.Since a critical step in LPS-induced NF-ğœ…B nuclearaccumulation and transcriptional activity is p65 and p50dissociation from Iğœ…B protein, this study investigated effectof torilin treatment in Iğœ…B and its kinase activity. Interest-ingly, we found that torilin inhibited LPS-induced IKKğ›¼/ğ›½activation, IkBğ›¼ phosphorylation, and decreased p65 andp50 nuclear translocation. In line with our findings, othersesquiterpenes have been shown to inhibit activation of NF-ğœ…B by preventing the degradation of I-ğœ…B-ğ›¼ and I-ğœ…B-ğ›½ [13],inhibiting NF-ğœ…B activation [40], and suppressing iNOS andCOX-2 expression through the inactivation of NF-kB [41] orby directly binding to and inhibiting I-ğœ…B kinase [14, 15].We, in the present study, observed that torilin pre-treatment suppressed MAPK and IKK mediated I-ğœ…B phos-phorylation, NF-ğœ…B and AP1 nuclear translocation, DNAbinding, and reporter transcriptional activation reflectingthe ability of torilin to inhibit NF- ğœ…B and AP-1 dependentinflammatorymediators and proinflammatory cytokine tran-scriptions. Such a strong effect of torilin on both IKK andMAPK activation in the present study suggests its role onearly common upstream signaling events. However, torilindid not affect MyD88, IRAK1, and TRAF6 downstream ofTLR4 but suppressed the signaling effects thereafter at thelevel of MAP3K complexes. Interestingly, torilin inhibitedTAK1 kinase activation and phosphorylationwith subsequentTAK1 mediated activation of kinases such as the I-ğœ…B kinaseand MAP kinases, which in turn modulate the transcrip-tional activities of the NF-kB and AP-1 families, respectively.However, the molecular mechanisms responsible for torilinmediated TAK1 inactivation remains to be addressed.Since TAK1, amember of theMAPKKK family, is thoughtto be a key modulator of adaptive and innate immunitythat mediates inducible transcription factors NF-ğœ…B and AP-1 and, therefore, plays a crucial role in regulating the genesthat mediate inflammation [30, 42], we thought that naturalcompounds such as torilin that target TAK1 activation maybe an attractive strategy to treat inflammatory responses.Thepresent study together with our previous report [26] indi-cated that torilin plays a crucial role against TAK1 mediatedcellular response to LPS-induced and collagen-induced [26]inflammatory stimuli. TAK1 is a critical integration checkpoint for innate and adapted immune responses upstream ofMAPkinase and I-kB kinase pathways [3, 43]. In linewith thisstudy, TAK1-deficient cells failed to activate NF-ğœ…B andMAPkinases in response to IL-1ğ›½, TNF, and TLR ligands [30]. Inaddition to its role in innate immunity, recent studies havedefined an essential role of TAK1 in T cell receptor- and B cellreceptor-induced activation of NF-kB and in the survival anddevelopment of immune cells, includingmature B cells and Tcells [3, 43â€“45]. In B cells, TAK1 is reported to be required forB cell development andNF-kB andMAPKactivation inducedby cytokines, TLR ligands, and BCR stimuli [3, 45].In conclusion, we demonstrate that torilin arrested LPS-induced TAK1 kinase activation with a subsequent suppres-sion in IKK-mediated I-ğœ…B phosphorylation NF-ğœ…B translo-cation. In addition, it attenuated TAK1 mediated MAPKsactivation and AP1 transactivation. Together, the data ledto suppression of NF-ğœ…B and AP-1 regulated inflammatorymediator and cytokine expressions, suggesting the test com-poundâ€™s potential as a candidate anti-inflammatory agent.AbbreviationsCOX-2: Cyclooxygenase-2GM-CSF: Granulocyte-macrophage colonystimulating factorIKK or Iğœ…B kinase: Inhibitory nuclear factor kappa-BkinaseIL-1ğ›½: Interleukin-1ğ›½IL-6: Interleukin-6iNOS: Inducible nitric oxide synthaseMAPKs: Mitogen activated protein kinasesNF-ğœ…B: Nuclear factor kappa-BNO: Nitric oxidePGE2: Prostaglandin E2PI3K: Phosphatidylinositol 3-phosphatePKB/Akt: Protein kinase BRT-PCR: Reverse transcription PCRTNF-ğ›¼: Tumor necrosis factor-ğ›¼TAK1: TGFğ›½-activated kinase 1TAB1/2: TGFğ›½-activated kinase 1 bindproteins 1 and 2.Competing InterestsThe authors declare no conflict of interests.AcknowledgmentsThis research was supported by the National Research Foun-dation of Korea Grant funded by the Korean government(Grant no. 2015R1D1A1A09057204) and by Research BaseConstruction Fund Support Program funded by ChonbukNational University in 2016.References[1] S. Akira and K. Takeda, â€œToll-like receptor signalling,â€ NatureReviews Immunology, vol. 4, no. 7, pp. 499â€“511, 2004.[2] Z. J. Chen, â€œUbiquitin signalling in the NF-ğœ…B pathway,â€NatureCell Biology, vol. 7, no. 8, pp. 758â€“765, 2005.12 Mediators of Inflammation[3] S. Sato, H. Sanjo, K. Takeda et al., â€œEssential function for thekinase TAK1 in innate and adaptive immune responses,â€NatureImmunology, vol. 6, no. 11, pp. 1087â€“1095, 2005.[4] M. Guha and N. Mackman, â€œLPS induction of gene expressionin human monocytes,â€ Cellular Signalling, vol. 13, no. 2, pp. 85â€“94, 2001.[5] N. J. Gay and M. Gangloff, â€œStructure and function of tollreceptors and their ligands,â€Annual Review of Biochemistry, vol.76, no. 1, pp. 141â€“145, 2007.[6] G. Bonizzi and M. Karin, â€œThe two NF-ğœ…B activation pathwaysand their role in innate and adaptive immunity,â€ Trends inImmunology, vol. 25, no. 6, pp. 280â€“288, 2004.[7] M. Endale, S.-C. Park, S. Kim et al., â€œQuercetin disrupts tyro-sine-phosphorylated phosphatidylinositol 3-kinase and mye-loid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-ğœ…B-induced inflammatory mediators pro-duction in RAW 264.7 cells,â€ Immunobiology, vol. 218, no. 12,pp. 1452â€“1467, 2013.[8] A.Deorukhkar, S. Krishnan, G. Sethi, and B. B. Aggarwal, â€œBackto basics: how natural products can provide the basis for newtherapeutics,â€ Expert Opinion on Investigational Drugs, vol. 16,no. 11, pp. 1753â€“1773, 2007.[9] A. Salminen, M. Lehtonen, T. Suuronen, K. Kaarniranta, and J.Huuskonen, â€œTerpenoids: natural inhibitors of NF-ğœ…B signalingwith anti-inflammatory and anticancer potential,â€ Cellular andMolecular Life Sciences, vol. 65, no. 19, pp. 2979â€“2999, 2008.[10] A.Kumar, Y. Takada,A.M.Boriek, andB. B.Aggarwal, â€œNuclearfactor-ğœ…B: its role in health and disease,â€ Journal of MolecularMedicine, vol. 82, no. 7, pp. 434â€“448, 2004.[11] P. Bremner and M. Heinrich, â€œNatural products as targetedmodulators of the nuclear factor-ğœ…B pathway,â€ Journal of Phar-macy and Pharmacology, vol. 54, no. 4, pp. 453â€“472, 2002.[12] T. Kawai and S. Akira, â€œSignaling to NF-ğœ…B by Toll-like rece-ptors,â€Trends inMolecularMedicine, vol. 13, no. 11, pp. 460â€“469,2007.[13] S. P. Hehner, M. Heinrich, P. M. Bork et al., â€œSesquiterpenelactones specifically inhibit activation of NF-ğœ…B by preventingthe degradation of Iğœ…B-ğ›¼ and Iğœ…B-ğ›½,â€ Journal of BiologicalChemistry, vol. 273, no. 3, pp. 1288â€“1297, 1998.[14] S. P. Hehner, T. G. Hofmann,W.DroÂ¨ge, andM. L. Schmitz, â€œTheantiinflammatory sesquiterpene lactone parthenolide inhibitsNF-ğœ…b by targeting the Iğœ…B kinase complex,â€ The Journal ofImmunology, vol. 163, no. 10, pp. 5617â€“5623, 1999.[15] B. H. B. Kwok, B. Koh, M. I. Ndubuisi, M. Elofsson, and C. M.Crews, â€œThe anti-inflammatory natural product parthenolidefrom the medicinal herb Feverfew directly binds to and inhibitsIğœ…Bkinase,â€Chemistry&Biology, vol. 8, no. 8, pp. 759â€“766, 2001.[16] A. J. GarcÂ´Ä±a-PinËœeres, V. Castro, G. Mora et al., â€œCysteine 38 inp65/NF-ğœ…B plays a crucial role in DNA binding inhibition bysesquiterpene lactones,â€The Journal of Biological Chemistry, vol.276, no. 43, pp. 39713â€“39720, 2001.[17] B. Siedle, A. J. GarcÄ±Â´a-PinËœeres, R. Murillo et al., â€œQuantita-tive structure-activity relationship of sesquiterpene lactonesas inhibitors of the transcription factor NF-ğœ…B,â€ Journal ofMedicinal Chemistry, vol. 47, no. 24, pp. 6042â€“6054, 2004.[18] I.-K. Lee, J.-H. Lee, E. I. Hwang, and B.-S. Yun, â€œNew guaianesesquiterpenes from the fruits of Torilis japonica,â€Chemical andPharmaceutical Bulletin, vol. 56, no. 10, pp. 1483â€“1485, 2008.[19] H. J. Youn, J. Lakritz, G. E. Rottinghaus et al., â€œAnti-protozoalefficacy of high performance liquid chromatography fractionsof Torilis japonica and Sophora flavescens extracts on Neosporacaninum and Toxoplasma gondii,â€ Veterinary Parasitology, vol.125, no. 3-4, pp. 409â€“414, 2004.[20] W.-I. Cho, J.-B. Choi, K. Lee, M.-S. Chung, and Y.-R. Pyun,â€œAntimicrobial activity of torilin isolated from Torilis japonicafruit against Bacillus subtilis,â€ Journal of Food Science, vol. 73,no. 2, pp. M37â€“M46, 2008.[21] S. E. Kim,Y.H.Kim,Y.C.Kim, and J. J. Lee, â€œTorilin, a sesquiter-pene from torilis japonica, reverses multidrug-resistance incancer cells,â€ Planta Medica, vol. 64, no. 4, pp. 332â€“334, 1998.[22] M. S. Kim, Y. M. Lee, E.-J. Moon, S. E. Kim, J. J. Lee, andK.-W. Kim, â€œAnti-angiogenic activity of torilin, a sesquiterpenecompound isolated fromTorilis japonica,â€ International Journalof Cancer, vol. 87, no. 2, pp. 269â€“275, 2000.[23] M. S. Kim, J. H. Baek, M. T. Park et al., â€œAnti-invasive activityof torilin, a sesquiterpene compound isolated from Torilisjaponica,â€ Oncology Reports, vol. 8, no. 2, pp. 359â€“364, 2001.[24] E. B. Lee, S. I. Cho, S. S. Kang, K. R. Kim, and T. H. Kim,â€œIsolation of torilin from Torilis japonica fruit and its analgesicand anti-inflammatory activities,â€ Korean Journal of Pharma-cognosy, vol. 30, no. 2, pp. 137â€“144, 1999.[25] Y. Choi, M. K. Lee, S. Y. Lim, S. H. Sung, and Y. C. Kim,â€œInhibition of inducible NO synthase, cyclooxygenase-2 andinterleukin-1ğ›½ by torilin is mediated by mitogen-activatedprotein kinases in microglial BV2 cells,â€ British Journal ofPharmacology, vol. 156, no. 6, pp. 933â€“940, 2009.[26] M. Endale,W.M. Lee, Y.-S. Kwak et al., â€œTorilin ameliorates typeII collagen-induced arthritis in mouse model of rheumatoidarthritis,â€ International Immunopharmacology, vol. 16, no. 2, pp.232â€“242, 2013.[27] M. Endale, S. D. Kim, W. M. Lee et al., â€œIschemia induces regu-lator of G protein signaling 2 (RGS2) protein upregulationand enhances apoptosis in astrocytes,â€ American Journal ofPhysiology - Cell Physiology, vol. 298, no. 3, pp. C611â€“C623, 2010.[28] J. A. DiDonato, M. Hayakawa, D. M. Rothwarf, E. Zandi, andM. Karin, â€œA cytokine-responsive IkappaB kinase that activatesthe transcription factor NF-kappaB,â€Nature, vol. 388, no. 6642,pp. 548â€“554, 1997.[29] M. Karin and M. Delhase, â€œThe Iğœ…B kinase (IKK) and NF-ğœ…B: key elements of proinflammatory signalling,â€ Seminars inImmunology, vol. 12, no. 1, pp. 85â€“98, 2000.[30] J.-H. Shim, C. Xiao, A. E. Paschal et al., â€œTAK1, but not TAB1or TAB2, plays an essential role in multiple signaling pathwaysin vivo,â€ Genes & Development, vol. 19, no. 22, pp. 2668â€“2681,2005.[31] J. A. Hoffmann, F. C. Kafatos, C. A. Janeway Jr., and R. A.B. Ezekowitz, â€œPhylogenetic perspectives in innate immunity,â€Science, vol. 284, no. 5418, pp. 1313â€“1318, 1999.[32] S. Ghosh, M. J. May, and E. B. Kopp, â€œNF-ğœ…B and rel proteins:evolutionarily conserved mediators of immune responses,â€Annual Review of Immunology, vol. 16, pp. 225â€“260, 1998.[33] S. Chen, â€œatural products triggering biological targetsâ€”a reviewof the anti-inflammatory phytochemicals targeting the arachi-donic acid pathway in allergy asthma and rheumatoid arthritis,â€Current Drug Targets, vol. 12, no. 3, pp. 288â€“301, 2011.[34] M. Caivano and P. Cohen, â€œRole of mitogen-activated pro-tein kinase cascades in mediating lipopolysaccharide-stimu-lated induction of cyclooxygenase-2 and IL-1ğ›½ in RAW264macrophages,â€ The Journal of Immunology, vol. 164, no. 6, pp.3018â€“3025, 2000.Mediators of Inflammation 13[35] N. R. Bhat, P. Zhang, J. C. Lee, and E. L. Hogan, â€œExtracel-lular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide syn-thase and tumor necrosis factor-ğ›¼ gene expression in endo-toxin-stimulated primary glial cultures,â€ The Journal of Neuro-science, vol. 18, no. 5, pp. 1633â€“1641, 1998.[36] J. J. Baldassare, Y. Bi, andC. J. Bellone, â€œThe role of p38mitogen-activated protein kinase in IL-1ğ›½ transcription,â€ The Journal ofImmunology, vol. 162, no. 9, pp. 5367â€“5373, 1999.[37] D. Hwang, B. C. Jang, G. Yu, and M. Boudreau, â€œExpression ofmitogen-inducible cyclooxygenase induced by lipopolysaccha-ride: mediation through both mitogen-activated protein kinaseand NF-ğœ…B signaling pathways in macrophages,â€ BiochemicalPharmacology, vol. 54, no. 1, pp. 87â€“96, 1997.[38] P. A. Scherle, E. A. Jones, M. F. Favata et al., â€œInhibition ofMAP kinase kinase prevents cytokine and prostaglandin E2production in lipopolysaccharide-stimulated monocytes,â€ TheJournal of Immunology, vol. 161, no. 10, pp. 5681â€“5686, 1998.[39] A. A. Ajibade, H. Y. Wang, and R.-F. Wang, â€œCell type-specificfunction of TAK1 in innate immune signaling,â€ Trends inImmunology, vol. 34, no. 7, pp. 307â€“316, 2013.[40] E. J. Kim, H. K. Jin, Y. K. Kim et al., â€œSuppression by a sesquiter-pene lactone from Carpesium divaricatum of inducible nitricoxide synthase by inhibiting nuclear factor-ğœ…B activation,â€Biochemical Pharmacology, vol. 61, no. 7, pp. 903â€“910, 2001.[41] J. Whan Han, B. Gon Lee, Y. Kee Kim et al., â€œErgolide,sesquiterpene lactone from Inula britannica, inhibits induciblenitric oxide synthase and cyclo-oxygenase-2 expression inRAW264.7 macrophages through the inactivation of NF-ğœ…B,â€ BritishJournal of Pharmacology, vol. 133, no. 4, pp. 503â€“512, 2001.[42] Y. Wang, G. Huang, P. Vogel, G. Neale, B. Reizis, and H. Chi,â€œTransforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells pro-motes immune homeostasis and function,â€ Proceedings of theNational Academy of Sciences of the United States of America,vol. 109, no. 6, pp. E343â€“E352, 2012.[43] Y. Y. Wan, H. Chi, M. Xie, M. D. Schneider, and R. A. Flavell,â€œThe kinase TAK1 integrates antigen and cytokine receptorsignaling for T cell development, survival and function,â€NatureImmunology, vol. 7, no. 8, pp. 851â€“858, 2006.[44] S. Sato, H. Sanjo, T. Tsujimura et al., â€œTAK1 is indispensablefor development of T cells and prevention of colitis by thegeneration of regulatory T cells,â€ International Immunology, vol.18, no. 10, pp. 1405â€“1411, 2006.[45] J. Schuman, Y. Chen, A. Podd et al., â€œA critical role of TAK1 in B-cell receptor-mediated nuclear factor ğœ…B activation,â€ Blood, vol.113, no. 19, pp. 4566â€“4574, 2009.Submit your manuscripts athttps://www.hindawi.comStem CellsInternationalHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014MEDIATORSINFLAMMATIONofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Behavioural NeurologyEndocrinologyInternational Journal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Disease MarkersHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014BioMed Research InternationalOncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Oxidative Medicine and Cellular LongevityHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014PPAR ResearchThe Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Journal ofObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014 Computational and  Mathematical Methods in MedicineOphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Research and TreatmentAIDSHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Parkinsonâ€™s DiseaseEvidence-Based Complementary and Alternative MedicineVolume 2014Hindawi Publishing Corporationhttp://www.hindawi.com